Skip to main content
. Author manuscript; available in PMC: 2017 Jul 7.
Published in final edited form as: Clin Cancer Res. 2015 Oct 21;22(6):1341–1347. doi: 10.1158/1078-0432.CCR-15-1441

Figure 2.

Figure 2

Correlation of tumor response over the first 12 weeks with overall survival in all patients on BRIM2. Responses were defined as 10%, 20%, 30%, 40%, 50%, or 60% reduction in the sum of the target lesions. The weighted C-index was normalized to range between 0 and 1, and SDs were calculated using bootstrapping. Tick marks, censored patients.